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Abstract 
The major hindrance for the absorption of a drug taken orally is 
extensive first pass metabolism or stability problems within the GI 
environment like instability in gastric pH and complexation with 
mucosal membrane. These obstacles can be overcome by altering the 
route of administration as parenteral, transdermal or trasmucosal. 
Among these trasmucosal has the advantage of ease of administration, 
patient compliance and are economic too. The mucosa of the buccal 
cavity is the most easily accessible transmuocosal site. Buccal 
transmucosal delivery helps to bypass first- pass metabolism by allowing 
direct access to the systemic circulation through the internal jugular 
vein. The buccal transmucosal route has been researched for a wide 
variety of drugs. Several methodologies have been considered so far, to 
design and manipulate the release properties towards the invention of 
buccal mucosal delivery systems. This article aims at reviewing the 
numerous techniques that has been designed till date for optimizing 
buccal transmucosal drug delivery. 
Keywords: complexation; parenteral; transdermal; trasmucosal 
Introduction 
Bioadhesion can be defined as the state in which 
two materials, at least one of which is biological 
in nature, are held together for extended periods 
of time by interfacial forces. When the adhesive 
attachment is to mucus or a mucous membrane, 
the phenomenon is referred to as mucoadhesion. 
[1] 
 
Mucoadhesion has become an interesting topic 
for research over the last two decades, for its 
potential to optimize localized drug delivery, by 
retaining dosage forms at the site of action or 
systemic delivery, by retaining a formulation in 
intimate contact with the absorption site. [2] 
Mucoadhesive formulations are usually prepared 
with mucoadhesive polymers. First generation 
mucoadhesive polymers are hydrophilic in 
nature, having limited solubility in other solvents, 
forming high viscous liquid in water and pH 
sensitive. These characteristics present significant  
 
challenges in the formulation development of 
mucoadhesive formulations. [3-4] 
 
Mucoadhesive polymers have been used to 
formulate tablets, patches, or microparticles, with 
the adhesive polymer forming the matrix into 
which the drug is dispersed, or the barrier through 
which the drug must diffuse. Mucoadhesive 
ointments and pastes consist of powdered 
bioadhesive polymers incorporated into a 
hydrophobic base. Solutions tend to be viscous 
due to the nature of the mucoadhesive materials. 
Other proposed mucoadhesive formulations 
include gels, vaginal rods, pessaries and 
suppositories. [5] 
 
Mechanism of mucoadhesion 
There are many chemical bonds responsible for 
the mucoadhesion. Ionic (where two oppositely 
charged ions attract each other via electrostatic 
interactions to form a strong bond), covalent 
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(where electrons are shared, in pairs, between the 
bonded atoms in order to fill the orbital in both) 
are the stronger bonds which help the formulation 
to adhere to the mucosa. The weaker bonds 
involved in mucoadhesion are hydrogen bonds, 
Van-der-Waals bonds and other hydrophobic 
bonds.  [6-7] The mechanism by which a 
mucoadhesive bond is formed will depend on the 
nature of the mucous membrane and 
mucoadhesive material, the type of formulation, 
the attachment process and the subsequent 
environment of the bond. It is understood that a 
single mechanism for mucoadhesion cannot be 
proposed for all the different occasions when 
adhesion occurs. But, an understanding of these 
mechanisms in each instance will assist the 
development of new, enhanced drug delivery 
systems.  
 
Many theories proposed for mucoadhesion. The 
most important ‘electronic theory’ suggests that 
electron transfer occurs upon contact of adhering 
surfaces due to differences in their electronic 
structure. This electron transfer may result in the 
formation of an electrical double layer at the 
interface, with subsequent adhesion due to 
attractive forces. The wetting theory considers 
surface and interfacial energies and is primarily 
applied to liquid systems. This theory proposes 
that as a prerequisite for the development of 
adhesion the liquid should have the ability to 
spread spontaneously onto a surface. The 
adsorption theory proposes that hydrogen 
bonding and van der Waals’ forces are the main 
contributors to the adhesive interaction. As per 
diffusion theory inter diffusion of polymers 
chains across an adhesive interface causes 
adhesion, and is driven by concentration gradient. 
Other theories proposed for mucoadhesion are the 
mechanical theory and the fracture theory. [8] 
Upon adhesion, the drug enters into the systemic 
circulation by different pathways like passive 
diffusion (transcellular and or paracellular), 
carrier mediated transport and endocytosis. 
 
 
 
Buccal drug delivery 
Difficulties associated with parenteral delivery 
and poor oral availability provided the impetus 
for exploring alternative routes for the delivery of 
such drugs. These include routes such as 
pulmonary, ocular, nasal, rectal, buccal, 
sublingual, vaginal, and transdermal. Substantial 
efforts have recently been focused on placing a 
drug or drug delivery system in a particular 
region of the body for extended periods of time. 
The mucosal layer lines a number of regions of 
the body including the oral cavity, gastro 
intestinal tract, the urogenital tract, the airways, 
the ear, nose and eye. Hence the mucoadhesive 
drug delivery system can be classified according 
to its potential site of applications. [9]        
 
The buccal region of oral cavity is an attractive 
site for the delivery of drugs owing to the ease of 
the administration. Buccal drug delivery involves 
the administration of desired drug through the 
buccal mucosal membrane lining of the oral 
cavity. This route is useful for mucosal (local 
effect) and transmucosal (systemic effect) drug 
administration. In the first case, the aim is to 
achieve a site-specific release of the drug on the 
mucosa, whereas the second case involves drug 
absorption through the mucosal barrier to reach 
the systemic circulation. [10] 
 
Based on current understanding of biochemical 
and physiological aspects of absorption and 
metabolism of many biotechnologically produced 
drugs, they cannot be delivered effectively 
through the conventional oral route. Because after 
oral administration many drugs are subjected to 
pre-systemic clearance extensive in liver, which 
often leads to a lack of significant correlation 
between membrane permeability, absorption, and 
bioavailability. Direct access to the systemic 
circulation through the external jugular vein by 
pass the drugs from the hepatic first pass 
metabolism which may lead to higher bio 
availability. Further these dosage forms are self 
administrable, cheap and have superior patient 
compliance. Unlike oral drug delivery which 
presents a hostile environment for drugs 
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especially proteins and peptides due to acid 
hydrolysis enzymatic degradation, hepatic first 
pass effect the mucosal lining of buccal tissues 
provides a much milder environment for drug 
absorption. In the case of both mucosal and trans-
mucosal administration, conventional dosage 
forms are not able to assure therapeutic drug 
levels on the mucosa and in the circulation. This 
is because of the physiological removal 
mechanisms of the oral cavity (washing effect of 
saliva and mechanical stress), which take the 
formulation away from the mucosa, resulting in a 
too short exposure time and unpredictable 
distribution of the drug on the site of 
action/absorption. [4] The advantages that make 
buccal adhesive drug delivery systems as 
promising option for continued research are listed 
in Table 1. 
 
 
Table 1:  Advantages of buccal drug delivery systems. 
 
• Excellent accessibility 
• Presence of smooth muscle and relatively 
immobile mucosa, hence suitable for 
administration of retentive dosage forms 
• Direct access to the systemic circulation 
through the internal jugular vein bypasses 
drugs from the hepatic first pass metabolism 
leading to high bioavailability 
• Low enzymatic activity 
• Suitability for drugs or excipients that mildly 
and reversibly damages or irritates the 
mucosa 
• Painless administration 
• Easy drug withdrawal 
• Facility to include permeation 
enhancer/enzyme inhibitor or pH modifier in 
the formulation 
• Versatility in designing as multidirectional or 
unidirectional release systems for local or 
systemic actions etc. 
  
However, low oral mucosal permeability of 
drugs, the effect of salivary scavenging and 
accidental swallowing of delivery system; barrier 
property of buccal mucosa stands as the major 
limitations in the development of buccal adhesive 
drug delivery systems. [4] 
 
Design of Formulations for buccal drug 
delivery 
Buccal adhesive drug delivery systems with the 
size 1–3 cm2 and a daily dose of 25 mg or less are 
preferable. The maximal duration of buccal 
delivery is approximately 4–6 h. [11] 
 
Pharmaceutical considerations 
To develop a safe and effective buccal adhesive 
drug delivery device great care needs to be 
exercised. Factors affecting the drug release, 
penetration through buccal mucosa, organoleptic 
factors, and effects of other excipients used to 
improve drug release pattern and absorption, 
irritation caused at the site of application are to be 
considered while designing a formulation. 
 
Ideally pharmaceutical buccal adhesive drug 
delivery systems should contain mucoadhesive 
agents, penetration enhancers and enzyme 
inhibitors. Mucoadhesive agents are used to 
maintain an intimate and prolonged contact of the 
formulation with the absorption site while 
penetration enhancers improve the drug 
permeation across mucosa (trans-mucosal 
delivery) or into deepest layers of the epithelium 
(mucosal delivery). The enzyme inhibitors ideally 
protect the drug from the degradation by means 
of mucosal enzymes. [12-14]  
 
Buccal adhesive polymers 
Mucoadhesive polymers are the important 
component in the development of buccal delivery 
systems. These polymers enable retention of 
dosage form at the buccal mucosal surface and 
thereby provide intimate contact between the 
dosage form and the absorbing tissue. These 
formulations are often water soluble and when in 
a dry form attract water from the biological 
surface which in turn leads to a strong interaction 
between the dosage form and mucosal layer. [15] 
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The mucoadhesive polymers most commonly 
used in buccal dry or partially hydrated dosage 
forms include polyacrylic acid, polyvinyl alcohol 
(PVA), sodium carboxymethylcellulose 
(NaCMC), hydroxypropylmethyl cellulose 
(HPMC), hydroxyethyl cellulose (HEC), 
hydroxypropyl cellulose (HPC), sodium alginate, 
chitosan and its derivatives, gelatin, carrageenan, 
lamellar and cubic liquid crystalline phases of 
glyceryl monooleate (GMO). [16-18] Various 
copolymers of acrylic acid (acrylic acid 
polyethylene glycol monomethyl ether copolymer 
and acrylic acid-2 ethylhexyl acrylate copolymer) 
have also been used. [4] 
 
Polymer morphology and excipients present are 
the main components that determine the release 
kinetics from the polymer matrix. Drug release 
from a polymeric material takes place either by 
the diffusion or by polymer degradation or by a 
combination of the both. Polymer degradation 
generally takes place by the enzymes or 
hydrolysis either in the form of bulk erosion or 
surface erosion. [3-18] 
 
Membrane permeation is the limiting factor for 
many drugs in the development of buccal 
adhesive delivery devices. However, examination 
of penetration route for trans-buccal delivery is 
important because it is fundamental to select the 
proper penetration enhancer to improve the drug 
permeability [19]. The different permeation 
enhancers that were extensively reviewed and 
reported in literatures are given in Table 2. [19-
23] 
 
Table 2: Different permeation enhancers used in buccal drug delivery. 
Class of permeation enhancers Examples 
Thiolated polymers 
 
Chitosan-4-thiobutylamide, chitosan- 4-
thiobutylamide/GSH, chitosan-cysteine, Poly 
(acrylic acid)-homocysteine, polycarbophil-
cysteine,polycarbophil-cysteine/GSH, chitosan-4-
thioethylamide/GSH, chitosan-4-thioglycholic 
acid 
Surfactants  Sodium lauryl sulphate, polyoxyethylene, 
Polyoxyethylene-9-lauryl ether, Polyoxythylene-
20-cetylether, Benzalkonium chloride, 23-lauryl 
ether, cetylpyridinium chloride, cetyltrimethyl 
ammonium bromide 
Chelators   
 
EDTA, citric acid, sodium salicylate, methoxy 
salicylates. 
Non-surfactants   Unsaturated cyclic ureas. 
Fatty acids  . 
 
Oleic acid, capric acid, lauric acid, lauric acid/ 
propylene glycol, methyloleate, 
lysophosphatidylcholine, phosphatidylcholine 
Inclusion complexes  Cyclodextrins. 
 
Bile salts . 
 
Sodium glycocholate, sodium deoxycholate, 
sodium taurocholate, sodium glycodeoxycholate, 
sodium taurodeoxycholate 
 
Others  
 
Aprotinin, azone, cyclodextrin, dextran sulfate, 
menthol, polysorbate 80, sulfoxides and various 
alkyl glycosides. 
However, the relative bioavailability of peptides 
by the buccal route was still low due to its poor 
permeation and enzymatic barrier of buccal 
mucosa but can be improved by the incorporation 
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of penetration enhancers and/or enzyme 
inhibitors. Enzyme inhibitors, such as aprotinin, 
bestatin, puromycin and some bile salts stabilize 
protein drugs by different mechanisms. [23] 
 
Physiological considerations 
Prior to the designing of buccal dosage form 
physiological factors such as texture of buccal 
mucosa, thickness of the mucus layer, its turn 
over time, effect of saliva and other 
environmental factors are to be considered. Saliva 
contains certain enzymes (esterases, 
carbohydrases, phosphatases) that may degrade 
some drugs. Although saliva secretion facilitates 
the dissolution of drug, involuntary swallowing 
of saliva also affects its bioavailability. These 
disadvantages can be avoided by developing 
unidirectional release systems with backing layer. 
This concept may also results in high drug 
bioavailability. [19-20] 
 
Pharmacological considerations 
The general principle of drug absorption holds 
good for buccal delivery also. Buccal drug 
absorption depends on the partition coefficient of 
the drugs. Lipophilic drugs absorb through the 
transcellular route, where as hydrophilic drugs 
absorb through the paracellular route. This 
behavior leads to the assumption that chemical 
modification may increase drug penetration 
through buccal mucosa. Increasing nonionized 
fraction of ionizable drugs increases drug 
penetration through trans-cellular route. In 
weakly basic drugs, the decrease in pH increases 
the ionic fraction of drug but decreases its 
permeability through buccal mucosa [24-25]. 
Other pharmacological factors include residence 
time and local concentration of the drug in the 
mucosa, the amount of drug transported across 
the mucosa into the blood. Earlier studies have 
demonstrated that oral mucosal absorption of 
amines and acids at constant concentration are 
proportional to their partition coefficients. 
Similar dependencies on partition coefficients 
were obtained from acyclovir, β- adrenoreceptor 
blocking agents and substituted acetanilide. [24] 
 
Dosage forms 
Several buccal adhesive delivery devices were 
developed at the laboratory scale by many 
researchers either for local or systemic actions 
and can be broadly classified in to solid buccal 
adhesive dosage forms, semi-solid buccal 
adhesive dosage forms and liquid buccal adhesive 
dosage forms. The various buccal dosage forms 
described in the literature are summarized in 
Table 3 and 4. The most common formulations 
are tablets and patches. 
 
Table 3: Buccal adhesive tablets described in literatures. 
  Class of Drug                 Bioadhesive polymer References 
NSAIDs   
Ketoprofen    
Nimesulide                                       
 
Chitosan and sodium alginate           
 
                 [26 ]    
                [27]                    
Calcium channel blockers  
 Nifedipine      
 Diltiazem                                         
 
Verapamil                                         
 
Chitosan, polycarbophil, Sodium 
alginate,gellan gum                    
CP 934 and PVP K-30 
 HPC-M, CP 934                              
 
                 [28]    
 
                 [29]     
                 [30-31]              
Beta blockers                                   
Propranolol       
Propranolol                                       
Propranolol     
Propranolol   
 
CP, HPMC, PC,SCMC, PAA, 
HPMC, CP 934        
HPMC, PC            
CP-934P, HPMC K4M                     
 
                 [32] 
                 [33]    
                 [32]       
                 [34]  
Anti fungal                                     
Nystain                                             
 
Carbomer, HPMC  
 
                 [35]        
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Clotrimazole                                     CP 974P, HPMC K4M                                     [36]                    
Corticosteroids  
Triamcilone 
Hydrocortisone Acetate   
 
 
Prednisolone   
 
Triamcilone                                      
                                                          
HPC, CP- 934    
HPMC (methocelk4m), Carbapol 
934P ,Polycarbiphyl           
                                                      
Polycarbophil and CP 934P  
                                                      
HPMC, PADH                                  
              
               [37] 
 
               [(38] 
 
               [39] 
   
               [40] 
Opoid analgesic  
Pentazocine                                       
Buprenorphine    
Morphine Sulphate                           
 
CP-934P, HPMC    
 HEMA and Polymeg 
Carbomer and HPMC                       
 
               [41] 
               [42] 
               [43] 
Proton pump inhibitor                   
Omeprazole                                      
 
Omeprazole 
 
Sodium alginate, HPMC, CP-
934P, PC   
Sodiun alginate and HPMC              
 
               [44]  
 
               [45]                     
COPD                       
Nicotine   
Nicotine Hydrogen tarterate             
 
HPC, CP-934P, PVP  
Aionic, cationic and nonionic           
 
              [46] 
              [47] 
Local anaesthetic      
Lidocaine                                          
 
CP-934, HPC-H                                
 
              [48] 
Anti bacterial  
Metronidazole                                   
 
CP-934, HPMC                                 
 
             [49] 
Anti histamine  
Chlorpheneramine                            
 
Hakea gum                                        
 
              [50] 
Osteophorosis 
Calcitonin                                         
 
Hakea gum                                        
 
              [50] 
Carminative and laxative 
  Citrus oil and Magnesium salt        
 
Cross linked PAA and HPC              
 
              [51] 
Anti-anxiety drugs  
Buspirone Hcl                                   
 
 
CP 974 HPMCK4M                         
 
             [52] 
Anti adrenergic drug  
Ergotamine Tartrate                          
 
PVA                                                 
 
             [53] 
Vasodilator  
Hydralazine 
Hcl                                                    
 
CP 934 and CMC                              
 
            [54] 
Anti parkinsonism  
 Piribedit                                           
  
            [55] 
Anti septic and disinfectant  
Cetyl Pyridinium Chloride               
  
            [56] 
  
 
 
 
 
 
 
176
Puratchikody et al. International Journal of Drug Delivery 3 (2011) 171-184 
 
Table 4: Buccal adhesive films described in literature. 
Class of  Drug Bioadhesive polymer References 
Biotechnology product 
Plasmid DNA 
 
Noveon, eudragit S-10 
 
[57] 
Anti oxidant 
Ipriflavone 
 
PLGA, Chitosan 
 
[58] 
Anti septic and disinfectant 
Chlorhexidine Gluconate 
 
Chitosan 
 
[59] 
Anti histamine 
Chlorpheneramine maleate 
 
Polyxyethylene 
 
[60] 
Opoid analgesic 
Buprenorphine 
 
CP-934, PIB and PIP 
 
[61] 
Anti anginal 
Isosorbide dinitrate 
 
HPC, HPMCP 
 
[62] 
Local anaesthetic 
Lidocaine 
 
HPC, CP 
 
[63] 
Anti fungal 
Miconazole nitrate 
 
SCMC, chitosan, PVA, HEC and HPMC 
 
[64] 
Calcium channel blockers 
Nifedipine 
 
Sodium alginate 
 
[65] 
Anti viral 
Acyclovir 
[ 
P (AA-co- PEG)] 
 
[66] 
 
Solid buccal adhesive formulations 
Solid buccal adhesive formulations achieve 
bioadhesion via dehydration of the local mucosal 
surface. They include tablets, micro particles, 
wafers, lozenges etc. Buccal adhesive tablets that 
are placed directly onto the mucosal surface for 
local or systemic drug delivery have been 
demonstrated to be excellent bioadhesive 
formulations. Two types of tablets i.e. monolithic 
and double-layered matrix tablets have been 
investigated for buccal delivery of drugs. 
Monolithic tablets consist of a mixture that 
contains drug and swelling bioadhesive/sustained 
release polymer. These tablets exhibit a 
bidirectional release. They can be coated on the 
outer or on all sides but one face with water 
impermeable hydrophobic substances to allow a 
unidirectional drug release for systemic delivery.  
 
Double layered tablets comprise an inner layer 
based on a bioadhesive polymer and an outer 
non-bioadhesive layer containing the drug for a 
bi-directional release but mainly a local action. In 
the case of systemic action, the drug is loaded 
into the inner bioadhesive layer whereas the outer 
layer is inert and acts as a protective layer. 
Alternatively, the drug is loaded into a controlled 
release layer and diffuses towards the absorbing 
mucosa through the bioadhesive layer, whereas a 
water impermeable layer assures the mono-
directional release. [26-29]  
 
Microparticles 
Bioadhesive microparticles offer the same 
advantages as tablets but their physical properties 
enable them to make intimate contact with a lager 
mucosal surface area. In addition, they can also 
be delivered to less accessible sites including the 
GI tract and upper nasal cavity. [19] 
 
Wafers 
A conceptually novel periodontal drug delivery 
system that is intended for the treatment of 
microbial infections associated with peridontitis 
was described elsewhere. . The delivery system is 
a composite wafer with surface layers possessing 
adhesive properties, while the bulk layer consists 
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of antimicrobial agents, biodegradable polymers 
and matrix polymers. [19] 
 
Lozenges 
Bioadhesive lozenges may be used for the 
delivery of drugs that act topically within the 
mouth including antimicrobials, corticosteroids, 
local anaesthetics, antibiotics and antifungals. 
[19] 
 
Semi-solid dosage forms 
Gels 
Gel forming bioadhesive polymers include 
crosslinked polyacrylic acid that has been used to 
adhere to mucosal surfaces for extended periods 
of time and provide controlled release of drugs. 
 
Patches/films.  
Flexible films may be used to deliver drugs 
directly to a mucosal membrane. They also offer 
advantages over creams and ointments in that 
they provide a measured dose of drug to the site. 
Buccal adhesive films are already in use 
commercially.[19] 
 
Patch systems are the formulations that have 
received the greatest attention for buccal delivery 
of drugs. They present a greater patient 
compliance compared with tablets owing to their 
physical flexibility that causes only minor 
discomfort to the patient. Patches are laminated 
and generally consist of an impermeable backing 
layer and a drug-containing layer that has 
mucoadhesive properties and from which the 
drug is released in a controlled manner. [19] 
Table 4 explains buccal adhesive films described 
in literatures.  
 
Liquid dosage forms 
Viscous liquids may be used to coat buccal 
surface either as protectants or as drug vehicles 
for delivery to the mucosal surface. 
 
A novel liquid aerosol formulation (Oralin, 
Generex Biotechnology) has been recently 
developed, and it is now in clinical phase II 
trials.This system allows precise insulin dose 
delivery via a metered dose inhaler in the form of 
fine aerosolized droplets directed into the mouth. 
[19] 
 
Commercially available buccal adhesive drug 
delivery systems 
Recent reports suggest that the market share of 
buccal adhesive drug delivery systems are 
increasing in the American and European market 
with the steady growth rate of above 10%. Some 
of the commercially available buccal adhesive 
formulations are listed in Table 5. 
Table 5: Commercially available buccal adhesive formulations [19]. 
Brand Name Bioadhesive 
Polymer 
Company Dosage forms 
 
 
Buccastem PVP, Xanthum gum, 
Locust bean gum 
Rickitt 
Benckiser 
Tablet 
 
Suscard HPMC Forest Tablet 
Gaviscon Liquid Sodium alginate Rickitt 
Benckiser 
Oral liquid 
Orabase Pectin,gelatin Orabase Pectin,gelatin 
Corcodyl gel HPMC Glaxosmithkline Oromucosal Gel 
Corlan pellets Acacia Celltech Oromucosal 
Pellets 
Fentanyl Oralet tm  Lexicomp Lozenge 
Miconaczole Lauriad  Bioalliance Tablet 
Emezine TM  BDSI’s  
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BEMA Fentanyl  BDSI’s  
Straint tm SR  Ardana  
Zilactin  Zila Buccal film 
Luborant Sodium CMC Antigen Artificial Saliva 
Saliveze Sodium CMC Wyvem Artificial Saliva 
Tibozole  Tibotec Tablet 
Aphtach 
 
Hydroxypropyl 
cellulose 
Polyacrylic acid 
Tejin Ltd Tablet 
Buccastem buccal Xanthan  gum Reckitt Tablet 
Povidone Benkner Plc   
Oralin – Gencrex 
 
Unknown Generex Biotechnology      
(Phase II  trials) 
Solution 
Lauriad        (Phase III  
trials) 
Unknown BioAlliance Pharma Tablet 
Striant SR buccal 
 
Carbomer 934P 
Hypromellose 
Polycarbophil 
Ardana Bioscience Ltd Tablet 
Suscard buccal Hypromellose Forest Laboratories Tablet 
 
Delivery of proteins and peptides 
The buccal mucosa represents a potentially 
important site for controlled delivery of 
macromolecular therapeutic agents, such as 
peptides and proteins. With the right dosage form 
design and formulation, the permeability and the 
local environment of the mucosa can be 
controlled and manipulated in order to 
accommodate drug permeation. Buccal drug 
delivery is a promising area for continued 
research with the aim of systemic delivery of 
orally inefficient drugs as well as a feasible and 
attractive alternative for non-invasive delivery of 
potent peptide and protein drug molecules. A 
variety of proteins/peptides with or without 
penetration enhancer were studied by different 
scientists using different animal models like dogs, 
rabbits, rats, pigs and humans. Some of those 
developments are represented in Table 6. 
 
Table 6: Buccal adhesive formulations of proteins/ peptides described in literature. 
Protein/peptide 
drug 
Dosage 
form 
Enhancer Animal 
model 
% increase in 
bioavailability 
references 
Buserelin 
 
Patch SGDC Pig, rat 12.7% [67] 
Calcitonin 
 
Tablet No enhancer Rabbits 37% [68] 
Captropil Tablet SGDC Humans  [69] 
Colony 
stimulating 
Patch No enhancer Dogs Two fold increase in  
Factor (G-SCF)    pharmacological action [70] 
Fnalapril Solution No enhancer Human No significant increase [71] 
Glucose like 
peptide 
Tablet STC Human 4 – 23% [72] 
Gonadotropin Tablet SC, SDC Dog SDC> SC>STC>STDC [73] 
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releasing       
Hormone 
STDC, STC 
Inteferorn Solution No enhancer Mice Marked increase (74) 
Insulin Liposomes No enhancer Rat No significant increase [75] 
Lisinopril Solution No enhancer Human No significant increase [71] 
Lutinizing 
hormone 
Releasing 
hormone 
Tablet SDC 5% Dog 273% [76] 
Octreotide 
acetate 
 Azone       
EDTA,STC 
Dog Azone>SC>EDTA>STC [77] 
Oxytoxin Patch No enhancer Rabbit Slight increase [78] 
Protrelin (TRH) Patch Citric acid 
Sodium 5- 
Methoxy 
salicylate 
Human 
Rats 
Increase  in  plasma 
thyrotropin concentration 
[79] 
Recombinant 
human 
Interferon alpha 
B/D 
Hybrid 
Solution No enhancer Rabbit,Rat 0.005% [80] 
 
Future challenges and opportunities 
The main impediment to the use of many 
hydrophilic macromolecular drugs as potential 
therapeutic agents is their inadequate and erratic 
oral absorption. The relatively recent evolution of 
recombinant DNA research and modern synthetic 
and biotechnological methodologies allow the 
biochemist and chemist to produce vast quantities 
of variety of peptides and proteins possessing 
better pharmacological efficacy. However, 
therapeutic potential of these compounds lies in 
our ability to design and achieve effective and 
stable delivery systems. The future challenge of 
pharmaceutical scientists will not only be 
polypeptide cloning and synthesis, but also to 
develop effective non-parenteral delivery of 
intact proteins and peptides to the systemic 
circulation. Buccal permeation can be improved 
by using various classes of transmucosal and 
transdermal penetration enhancers such as bile 
salts, surfactants, fatty acids and derivatives, 
chelators and cyclodextrins. [19] 
 
Researchers are now looking beyond traditional 
polymer networks to find other innovative drug 
transport systems. Much of the development of 
novel materials in controlled release buccal 
adhesive drug delivery is focusing on the 
preparation and use of responsive polymeric  
system using copolymer with desirable 
hydrophilic/hydrophobic interaction, block or 
graft copolymers, complexation networks 
responding via hydrogen or ionic bonding and 
new biodegradable polymers especially from 
natural edible sources. At the current global 
scenario, scientists are finding ways to develop 
buccal adhesive systems through various 
approaches to improve the bioavailability of 
orally less/inefficient drugs by manipulating the 
formulation strategies like inclusion of pH 
modifiers, enzyme inhibitors, permeation 
enhances etc. Novel buccal adhesive delivery 
system, where the drug delivery is directed 
towards buccal mucosa by protecting the local 
environment is also gaining interest. Currently 
solid dosage forms, liquids and gels applied to 
oral cavity are commercially successful. The 
future direction of buccal adhesive drug delivery 
lies in vaccine formulations and delivery of small 
proteins/peptides. Microparticulate bioadhesive 
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systems are particularly interesting as they offer 
protection to therapeutic entities as well as the 
enhanced absorption that result from increased 
contact time provided by the bioadhesive 
component. Exciting challenges remain to 
influence the bioavailability of drugs across the 
buccal mucosa. Many issues are yet to be 
resolved before the safe and effective delivery 
through buccal mucosa. Successfully developing 
these novel formulations requires assimilation of 
a great deal of emerging information about the 
chemical nature and physical structure of these 
new materials. [19] 
 
Conclusion 
The need for research into drug delivery systems 
extends beyond ways to administer new 
pharmaceutical therapies. The safety and efficacy 
of current treatments may be improved if their 
delivery rates, biodegradation, and site specific 
targeting can be predicted, monitored and 
controlled. From both a financial and global 
healthcare perspective, finding ways to 
administer injectable medications is costly and 
some time leads to serious hazardous effects. 
Hence inexpensive multiple dose formulations 
with better bioavailability are needed. Improved 
methods of drug release through trans-mucosal 
and transdermal methods would be of great 
significance, as by such routes, the pain factor 
associated with parenteral routes of drug 
administration can be totally eliminated. Buccal 
adhesive systems offer innumerable advantages 
in terms of accessibility, administration and 
withdrawal, retentivity, low enzymatic activity, 
economy and high patient compliance. Since the 
introduction of Orabase in 1947, when gum 
tragacanth was mixed with dental adhesive 
powder to apply penicillin to the oral mucosa; the 
market share of bioadhesive drug delivery 
systems is increasing. The growth rate for 
transmucosal drug delivery systems is expected 
to increase 11% annually through 2007. 
Worldwide market revenues are at $3B with the 
U.S. at 55%, Europe at 30% and Japan at 10%. 
[19] 
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